deliv better-than-anticip result organ growth
neg top compani neg neg
guidanc rang organ growth world-wide hip knee
implant market track littl wors initi anticip
approxim year-over-year zbh market share loss appear
lessen quarter current model roughli bp year-
over-year declin versu bp year-over-year declin quarter
million ep upsid modest compani stepped-up
invest commerci organ product commerci effort
new product develop effort drive organ growth near-
zbh commentari regard remaind mix
although see investor appear view favor
posit standpoint reiter expect product suppli
return normal level earli compani
ceo bryan hanson indic greater level confid
prospect given step complet past three month
addit suggest fda complet inspect biomet
warsaw manufactur facil recent manag believ
make progress address fda concern although
fda observ result inspect lastli product launch
intend address gap zbh knee portfolio remain track full
launch cementless knee plan limit releas rosa
total knee applic schedul full rollout rosa total
knee applic persona revis knee
prior consensu expect adjust ep growth high
specif compani current expect gross margin expans
next year given linger impact capit increas
product qualiti remedi cost addit anticip
modest sg expens leverag said new manag
clearli conserv guidanc would guess investor believ
compani take similar approach comment
total debt total asset
maintain adjust ep estim reduc
adjust ep outlook compani reflect
lower adjust oper margin assumpt overal view zbh updat
earn call mix would like see fda observ
recent inspect biomet warsaw manufactur facil
accept conclus rate remain neutral
import pleas read disclosur disclaim page report
report adjust ep consensu expect higher
estim rel forecast strong revenu off-set slightli higher tax rate modestli
wors net interest expens expens minor interest model
zbh revenu increas year-over-year million consensu expect
million million estim quarter zbh organ growth neg
includ impact one less sell day year-over-year outlook neg neg
well neg forecast revenu contribut currenc chang also
million guidanc although think expect achiev modest upsid
consensu revenu estim given jnj clear market share loss knee well currenc movement
believ report organ growth still slightli posit surpris
adjust incom statement analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom margin com share compani report northcoast research estim factset
product categori standpoint better-than-anticip organ growth zbh hip knee
surgic sport medicin extrem trauma busi account upsid rel
revenu outlook organ growth world-wide hip knee implant market track
littl wors initi anticip approxim year-over-year zbh market share loss
appear lessen quarter current model roughli bp year-over-year declin versu
bp year-over-year declin quarter last year
knee post organ growth neg neg estim
organ growth world-wide knee implant market appear declin roughli bp sequenti
posit neg sequenti deceler zbh knee organ growth
closer bp geograph standpoint zbh emea knee busi rel strong flat year-over-
year despit pressur delay elect procedur unit kingdom januari due
sever flu season america asia pacif knee busi year-over-year
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim reflect product suppli issu larg year-over-year price reduct india respect total zbh
knee price growth declin year-over-year slight improv year-over-
continu believ product suppli product gap drive market share loss knee regard
product gap compani continu expect full launch persona trabecular metal cementless tibia
persona revis knee rosa total knee applic also slate limit launch
back half year full launch given time launch zbh knee implant
busi like continu grow market rate anoth five quarter even address suppli issu
complet product launch in-lin forecast
hip post neg organ growth well neg forecast unlik knee
saw sequenti improv america hip organ growth posit year-over-year
posit year-over-year despit difficult market condit product suppli condit
began improv segment compani asia pacif hip busi also remain rel strong
organ emea hip busi organ show sign elect procedur delay
unit kingdom similar knee year-over-year price declin zbh hip busi year-over-
year versu year-over-year declin bad quarter particularli weak close
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast
zbh adjust oper margin declin bp year-over-year consist
forecast quarter adjust gross margin fell bp year-over-year reflect cost biomet
warsaw manufactur facil neg price growth year-over-year currenc movement
lack product gain focus effort remedi addit compani adjust sg
expens increas bp year-over-year percent sale driven invest sale forc
product commerci effort intend drive organ growth near-to-intermedi term
beyond zbh commentari regard remaind mix although see
investor appear view favor posit standpoint reiter expect
product suppli return normal level earli compani ceo bryan hanson
indic greater level confid prospect given step complet past
three month includ verif valid work complex manufactur process
outsourc biomet warsaw product facil contract manufactur addit suggest
fda complet inspect biomet warsaw manufactur facil recent manag believ
inc hip organ growth analysi reflect pro forma result zimmer biomet compani report northcoast inc quarterli total compani price growth year-over-year compani make progress address fda concern although fda observ result
inspect lastli product launch intend address gap zbh knee portfolio remain track
discuss
neg standpoint zbh initi comment regard suggest prior consensu expect
adjust ep growth high specif compani current expect gross margin expans
next year given linger impact capit increas product qualiti remedi cost
addit anticip modest sg expens leverag said new manag clearli
conserv guidanc would guess investor believ compani take similar approach
comment regard mid-point zbh adjust ep guidanc year
lower prior consensu expect think below-consensu guidanc
larg anticip head earn releas
manag reiter expect month turnaround busi compani
believ first full year grow market rate current base mix busi
expect faster plan look aggress portfolio manag increas
exposur faster grow market segment stabil busi addit manag think
compani reach above-market growth point full year
maintain adjust ep estim reduc adjust ep outlook
compani reflect lower adjust oper margin assumpt overal view zbh
updat earn call mix would like see fda observ recent
inspect biomet warsaw manufactur facil accept conclus rate
guidanc performancerevenu growth currenc growth constant currenc growth yr/yr organ growth yr/yr acquisit growth oper interest expens tax ep growth yr/yr neg compani report northcoast research estim includ cayenn medic med-tech sa acquir revenu includ organ growth
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth exclud amort intang asset adjust ep start compani report northcoast research estim disclosur
